[go: up one dir, main page]

GB201807367D0 - Biomarker - Google Patents

Biomarker

Info

Publication number
GB201807367D0
GB201807367D0 GBGB1807367.6A GB201807367A GB201807367D0 GB 201807367 D0 GB201807367 D0 GB 201807367D0 GB 201807367 A GB201807367 A GB 201807367A GB 201807367 D0 GB201807367 D0 GB 201807367D0
Authority
GB
United Kingdom
Prior art keywords
biomarker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1807367.6A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Newcastle University of Upon Tyne
Original Assignee
Newcastle University of Upon Tyne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newcastle University of Upon Tyne filed Critical Newcastle University of Upon Tyne
Priority to GBGB1807367.6A priority Critical patent/GB201807367D0/en
Publication of GB201807367D0 publication Critical patent/GB201807367D0/en
Priority to PCT/GB2019/051240 priority patent/WO2019211626A1/en
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911Bacteria
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/33Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GBGB1807367.6A 2018-05-04 2018-05-04 Biomarker Ceased GB201807367D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1807367.6A GB201807367D0 (en) 2018-05-04 2018-05-04 Biomarker
PCT/GB2019/051240 WO2019211626A1 (en) 2018-05-04 2019-05-03 Biomarker

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1807367.6A GB201807367D0 (en) 2018-05-04 2018-05-04 Biomarker

Publications (1)

Publication Number Publication Date
GB201807367D0 true GB201807367D0 (en) 2018-06-20

Family

ID=62598230

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1807367.6A Ceased GB201807367D0 (en) 2018-05-04 2018-05-04 Biomarker

Country Status (2)

Country Link
GB (1) GB201807367D0 (en)
WO (1) WO2019211626A1 (en)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US7129337B1 (en) 1994-10-21 2006-10-31 Innogenetics N.V. Sequences of hepatitis C virus genotypes and their use as prophylactic, therapeutic and diagnostic agents
US5756662A (en) 1995-03-14 1998-05-26 Corixa Corporation Compounds and methods for the detection of T. cruzi infection
IE20020097A1 (en) * 2001-02-09 2003-05-28 Trinity College Dublin A vaccine
DE60215819T2 (en) 2001-08-03 2007-09-06 Tyco Healthcare Group Lp, Norwalk MARKER FOR USE WITH A TISSUE MARKING DEVICE
JP5965389B2 (en) * 2010-04-15 2016-08-03 プロゲニクス ファーマシューティカルズ インコーポレーテッドProgenics Pharmaceuticals, Inc. Antibodies for the treatment of Clostridium difficile-related infections and diseases
US20140127215A1 (en) * 2010-12-29 2014-05-08 Cangene Corporation Clostridium difficile antigens

Also Published As

Publication number Publication date
WO2019211626A1 (en) 2019-11-07

Similar Documents

Publication Publication Date Title
GB2566681B (en) Biomarker
GB201614455D0 (en) Biomarkers
SG10202007262PA (en) Copanlisib biomarkers
GB201703058D0 (en) Biomarkers
SG10202007322PA (en) Copanlisib biomarkers
ZA202001821B (en) Biomarker
GB201710858D0 (en) Biomarker
GB201704267D0 (en) Novel biomarker
GB201902077D0 (en) Biomarkers
GB201900677D0 (en) Biomarkers
GB201804648D0 (en) Combination biomarker
GB201703123D0 (en) Biomarkers
GB201811093D0 (en) Biomarker
ZA202102664B (en) Chromosome biomarker
GB201913846D0 (en) Biomarker
GB201912154D0 (en) Biomarker
GB201911078D0 (en) Biomarker
SMT202300247T1 (en) Triazacyclododecansulfonamide (
GB201914183D0 (en) Biomarker
GB201913612D0 (en) Biomarker
GB201807367D0 (en) Biomarker
GB201809868D0 (en) Biomarkers
GB201809873D0 (en) Biomarkers
GB201809881D0 (en) Biomarkers
GB201809882D0 (en) Biomarkers

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)